Biocon Ltd
BIOCONBiocon Ltd
BIOCON![](https://assets.tickertape.in/sector-icons/health_care.png)
![](https://assets.tickertape.in/sector-icons/midcap.png)
![](https://assets.tickertape.in/sector-icons/moderate_risk.png)
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
26.92 | 1.68 | 0.14% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast from 15 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.
Peers
Compare with peersHester Biosciences Ltd
Panacea Biotec Ltd
Zenotech Laboratories Ltd
Transgene Biotek Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 3,716.70 | 4,064.50 | 4,350.90 | 5,854.30 | 6,529.40 | 7,410.20 | 8,396.70 | 11,550.10 | 15,621.20 | 16,725.70 | ||||||||||
Raw Materials | 1,330.90 | 1,515.60 | 1,677.80 | 2,106.30 | 2,190.30 | 2,533.80 | 2,975.00 | 3,817.20 | 5,754.60 | 11,645.10 | ||||||||||
Power & Fuel Cost | 184.70 | 156.40 | 189.00 | 239.80 | 246.10 | 270.30 | 316.40 | 414.80 | 388.90 | |||||||||||
Employee Cost | 610.10 | 747.00 | 931.10 | 1,165.30 | 1,458.80 | 1,741.00 | 1,880.10 | 2,181.00 | 2,664.10 | |||||||||||
Selling & Administrative Expenses | 524.50 | 540.10 | 519.30 | 846.70 | 952.70 | 1,041.70 | 1,158.10 | 1,338.60 | 1,725.80 | |||||||||||
Operating & Other expenses | 37.20 | -47.50 | -22.90 | -237.40 | -121.60 | -17.10 | 202.20 | 1,369.30 | 1,019.40 | |||||||||||
EBITDA | 1,029.30 | 1,152.90 | 1,056.60 | 1,733.60 | 1,803.10 | 1,840.50 | 1,864.90 | 2,429.20 | 4,068.40 | 5,080.60 | ||||||||||
Depreciation/Amortization | 248.70 | 277.20 | 385.10 | 447.80 | 552.20 | 715.10 | 814.20 | 1,113.10 | 1,568.80 | 1,616.20 | ||||||||||
PBIT | 780.60 | 875.70 | 671.50 | 1,285.80 | 1,250.90 | 1,125.40 | 1,050.70 | 1,316.10 | 2,499.60 | 3,464.40 | ||||||||||
Interest & Other Items | 29.30 | 26.00 | 61.50 | 70.90 | 64.90 | 57.70 | 67.60 | 419.00 | 974.40 | 977.40 | ||||||||||
PBT | 751.30 | 849.70 | 610.00 | 1,214.90 | 1,186.00 | 1,067.70 | 983.10 | 897.10 | 1,525.20 | 2,487.00 | ||||||||||
Taxes & Other Items | 200.90 | 237.60 | 237.60 | 309.60 | 437.80 | 327.20 | 334.70 | 434.40 | 502.70 | 906.20 | ||||||||||
Net Income | 550.40 | 612.10 | 372.40 | 905.30 | 748.20 | 740.50 | 648.40 | 462.70 | 1,022.50 | 1,580.80 | ||||||||||
EPS | 4.59 | 5.10 | 3.10 | 7.54 | 6.23 | 6.17 | 5.40 | 3.85 | 8.52 | 13.17 | ||||||||||
DPS | 0.83 | 0.50 | 0.50 | 0.50 | 0.00 | 0.00 | 0.50 | 1.50 | 0.50 | 1.50 | ||||||||||
Payout ratio | 0.18 | 0.10 | 0.16 | 0.07 | 0.00 | 0.00 | 0.09 | 0.39 | 0.06 | 0.11 |
Company Updates
Peers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Biocon Ltd | 41.62 | 1.68 | 0.14% |
Hester Biosciences Ltd | 106.80 | 6.66 | 0.25% |
Panacea Biotec Ltd | -942.08 | 1.68 | — |
Zenotech Laboratories Ltd | 51.60 | 5.21 | — |
Price Comparison
Compare BIOCON with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Biocon Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI CONTRA FUND DIRECT PL GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.2967% | Percentage of the fund’s portfolio invested in the stock 1.61% | Change in the portfolio weight of the stock over the last 3 months -0.09% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 15/111 (-3) |
Kotak Equity Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0218% | Percentage of the fund’s portfolio invested in the stock 1.73% | Change in the portfolio weight of the stock over the last 3 months 1.11% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/74 (+16) |
SBI Balanced Advantage Fund - Direct Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8533% | Percentage of the fund’s portfolio invested in the stock 1.13% | Change in the portfolio weight of the stock over the last 3 months 0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 70/128 (0) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 5, 2024
Dividend/Share
₹0.50
Ex DateEx Date
Jul 5, 2024
Cash Dividend
Ex DateEx DateJul 7, 2023
Dividend/Share
₹1.50
Ex DateEx Date
Jul 7, 2023
Cash Dividend
Ex DateEx DateJun 30, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Jun 30, 2022
Cash Dividend
Ex DateEx DateJul 18, 2019
Dividend/Share
₹0.50
Ex DateEx Date
Jul 18, 2019
Cash Dividend
Ex DateEx DateJul 19, 2018
Dividend/Share
₹1.00
Ex DateEx Date
Jul 19, 2018
In a regulatory filing, the company said that Biocon Biologics has has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson, collectively known as Janssen. This pact enables Biocon Biologics to commercialize its Bmab 1200, a proposed biosimilar to Stelara, in Europe, the United Kingdom (UK), Canada, and Japan. Under the terms of this settlement agreement, Biocon Biologics has resolved patent disputes with Janssen to secure market entry dates in the above mentioned regions. Regulatory filings for Bmab 1200 are currently under review. Stelara (Ustekinumab) is a monoclonal antibody medication that prevents abnormal regulation of interleukin IL-12/23 associated immune diseases and has been approved for the treatment of psoriasis, Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. The reference brand, Stelara, had worldwide sales of $10.85 billion in 2023. Shreehas Tambe, CEO & managing director, Biocon Biologics, said, 'This settlement agreement is testament to our proven track record of science and innovation and is another key milestone in our journey to bring our biosimilar Bmab 1200 (bUstekinumab) to global markets. Bmab 1200 will significantly strengthen our immunology franchise, enabling us to offer an affordable and effective treatment option for patients impacted by autoimmune diseases.' Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025, once approved by the U.S. FDA. The U.S. FDA has accepted the company's Biologics License Application (BLA) for Bmab 1200 (bUstekinumab) for review under the 351(k) pathway. Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The company's conosldidated net profit surged to Rs 659.7 crore in Q1 FY25 as compared with Rs 101.4 crore in Q1 FY24. Revenue from operations increased marginally year on year to Rs 3,432.9 crore in during the quarter. Shares of Biocon shed 0.81% to Rs 354 on the BSE. Powered by Capital Market - Live
Biocon Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 358.2, up 0.9% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.22% on the day, quoting at 24824.75. The Sensex is at 81098.08, up 0.24%. Biocon Ltd has risen around 6.28% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 8.74% in last one month and is currently quoting at 22577.9, down 0.04% on the day. The volume in the stock stood at 16.17 lakh shares today, compared to the daily average of 43.38 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 359.2, up 1.13% on the day. Biocon Ltd is up 37.58% in last one year as compared to a 27.67% spurt in NIFTY and a 47.68% spurt in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending June 24.Powered by Capital Market - Live
Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 348.6, up 1.1% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.57% on the day, quoting at 24712.8. The Sensex is at 80888.47, up 0.58%. Biocon Ltd has risen around 3.95% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 7.97% in last one month and is currently quoting at 22237.85, up 0.22% on the day. The volume in the stock stood at 34.09 lakh shares today, compared to the daily average of 43.07 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 348.95, up 1.16% on the day. Biocon Ltd is up 34.36% in last one year as compared to a 27.43% spurt in NIFTY and a 45.34% spurt in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending June 24.Powered by Capital Market - Live
Revenue from operations increased marginally YoY to Rs 3,432.9 crore in during the quarter. Total income jumped 29.9% to Rs 4,567.4 crore in Q1 FY25 as compared with Rs 3,516.1 crore in Q1 FY24. It includes proceeds of Rs 1,057 crore on account of the strategic collaboration between Biocon Biologics & Eris Lifesciences. Profit before exceptional items and tax stood at Rs 1113.5 crore in Q1 FY25, steeply higher than Rs 183.7 crore in Q1 FY24. Exceptional items stood at Rs 320 crore in Q1 FY25. During the quarter, EBITDA soared to Rs 1,755 crore as compared with Rs 808 crore posted in same quarter last fiscal. EBITDA margins expanded to 38% in Q1 FY25 as against 23% in Q1 FY24. Net R&D expenses fell 28% to Rs 228 crore during the quarter from Rs 315 crore recorded in corresponding quarter last year, representing 9% of revenue ex-Syngene. On segmental front, revenue from biosimilar stood at Rs 2,083 crore in Q1 FY25, up 3% from Rs 2,015 crore in Q1 FY24. On like-for-like basis, revenue jumped 11%. Revenue does not include proceeds of Rs 1,057 core on account of the strategic collaboration and business transfer to Eris Lifesciences which is booked as other income. Income from generics business fell 6% to Rs 659 crore in the first quarter of FY25 as compared with Rs 700 crore in Q1 FY24 and Revenue from research services (Syngene) declined 2% YoY to Rs 790 crore in Q1 FY25. Kiran Mazumdar-Shaw, executive chairperson, Biocon and Biocon Biologics, said, 'The outlook for this fiscal remains positive as we anticipate stronger growth in H2FY25, with new product launches in the Biosimilars and Generics businesses, including Liraglutide for diabetes and obesity in the UK and other markets. Additionally, we expect improved business prospects for Syngene, supported by a resurgent biotech funding environment in the U.S. Siddharth Mittal, CEO & managing director, Biocon, said, 'The Generics business continued to encounter pricing pressure and demand contraction, which impacted our first quarter's performance of both APIs and Generic Formulations. The business made progress on its Most of the World (MoW) expansion strategy with the signing of a partnership agreement with Handok in South Korea for the commercialization of Liraglutide. We also obtained our first injectable approval in the U.S. for Micafungin and secured some key customer contracts in the region. Looking ahead, our focus will be directed towards commercializing products for which we have received approvals, including Liraglutide, in the second half of this fiscal, as indicated previously. We will also continue to accelerate our cost improvement initiatives and expedite on-going capex projects.' Shreehas Tambe, CEO & managing director, Biocon Biologics, said, 'We began the fiscal year on a strong note with the business delivering year-on-year growth of 11% on a like-for-like basis. This growth was underpinned by an increase in market shares, tender wins in Europe and Emerging Markets and 15 new product launches.' Jonathan Hunt, CEO & managing director, Syngene International, said, ''First quarter performance was broadly flat, in line with our expectations, reflecting the dip in funding for U.S. biotechs that has impacted our sector over the last two years. However, the value of U.S. biotech funding has seen a marked improvement in the first half of 2024. It will take a while for this funding to flow through into outsourcing activities and Syngene is in a strong position to capture a significant share of the upturn in biotech spending in the months ahead.' Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The counter shed 0.57% to Rs 337.25 on the BSE.Powered by Capital Market - Live
Net profit of Biocon rose 550.59% to Rs 659.70 crore in the quarter ended June 2024 as against Rs 101.40 crore during the previous quarter ended June 2023. Sales rose 0.30% to Rs 3432.90 crore in the quarter ended June 2024 as against Rs 3422.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3432.903422.60 0 OPM %18.0719.90 - PBDT1518.90541.70 180 PBT1113.50183.70 506 NP659.70101.40 551 Powered by Capital Market - Live
Stocks in news: RIL, Airtel, Vedanta, ONGC, Adani Energy, Lupin and Biocon
![](https://pocket-image-cache.com/direct?url=http://akm-img-a-in.tosshub.com/businesstoday/images/story/202408/66b18a054da4b-pfc--vedanta--tata-power--bosch--shree-cement--cummins-india--tvs-motor--lupin--pb-fintech--gujarat-062715797-16x9.jpg)
Buy Biocon, target price Rs 390: Axis Securities
![](https://pocket-image-cache.com/direct?url=http://img.etimg.com/thumb/msid-112305225,width-1200,height-630,imgsize-91161,overlay-etmarkets/photo.jpg)
Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25
![](https://pocket-image-cache.com/direct?url=http://img.etimg.com/thumb/msid-112229764,width-1200,height-630,imgsize-6000,overlay-etmarkets/photo.jpg)
![](https://i.ytimg.com/vi/VUq0BtpnD-8/hqdefault.jpg?sqp=-oaymwEiCKgBEF5IWvKriqkDFQgBFQAAAAAYASUAAMhCPQCAokN4AQ==&rs=AOn4CLAGOaXi-uhtKukVAa4JfvE1iSgkDw)
Biocon Ltd spurts 3.48%, gains for five straight sessions
![](https://pocket-image-cache.com/direct?url=http://www.business-standard.com/assets/web-assets/images/Business_Standard_685x385.jpg)
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 21.69%, vs industry avg of 19.21%
Increasing Market Share
Over the last 5 years, market share increased from 84.66% to 93.82%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 2.46%, vs industry avg of 1.42%